Celularity and DefEYE Partner to Advance Eye Care Therapies
🕓 Estimated Reading Time: 5 minutes Overview In a move poised to significantly reshape the landscape of ophthalmic medicine, biotechnology firm Celularity Inc. and eye care innovator DefEYE Inc. have announced a strategic alliance aimed at accelerating the development and commercialization of advanced regenerative therapies for various eye conditions. This pivotal Celularity DefEYE partnership represents a concerted effort to leverage cutting-edge cellular technologies to address a wide spectrum of visual impairments, offering new hope to millions worldwide grappling with debilitating eye diseases. The collaboration will combine Celularity’s expertise in allogeneic placental-derived cell therapies with DefEYE’s deep understanding of ocular diseases and clinical development pathways in ophthalmology. This synergy is expected to fast-track the translation of novel therapeutic concepts into tangible treatments, potentially revolutionizing how age-related macular degeneration, diabetic r...